Superbacteria Targeting Phage Selection via 340 Genome Comparisons Accelerates Carbapenem-Resistant Bacteria Treatment
Background
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a multidrug-resistant bacterium that is difficult to treat with existing antibiotics. It causes hospital-acquired infections and has a high mortality rate, and the World Health Organization (WHO) has classified it as a pathogen that requires urgent action. Recently, phage therapy, which uses bacteriophages (viruses that kill bacteria) to overcome antibiotic resistance, has emerged as an alternative.
However, finding potent and safe phages suitable for clinical use is not easy. There was no clear criterion for selecting phages with excellent killing ability and no toxicity or resistance genes among the many phages. The performance of neutralizing bacterial immune systems also varies, so a selection guideline based on the genome is needed. This study established a multifaceted genomic evaluation framework to increase the success rate of phage therapy.
Key Findings
Large-Scale Comparative Analysis of 340 Genomes
The researchers analyzed the genomes of 340 Acinetobacter bacteriophages to elucidate their evolutionary characteristics. The results showed that the size of the phage genome varied by about 20-fold, and a negative correlation (R²=0.139, ρ=-0.630) was observed, with larger sizes associated with lower guanine-cytosine content (GC content).
Phylogenetic reconstruction revealed diversity with multiple lineages evenly distributed, with no specific dominant clade. Pangenome analysis of the phage population identified a total of 20,982 unique protein families. Among these, 76.2% were in the form of 'cloud genes' unique to specific phages. This indicates that Acinetobacter phages have a flexible, open genome structure to cope with host bacterial defense mechanisms and environmental changes.
Retrospective Analysis of Infection History and Safety Verification
To elucidate the infection history of phages and bacteria, CRISPR spacer analysis was introduced. The analysis revealed that 1,480 matching signals were identified in the genomes of 100 phages, demonstrating at the molecular level that they have infected multiple Acinetobacter strains.
In particular, the Anti-CRISPR profiling, which neutralizes the bacterial immune system, is noteworthy. The researchers identified 55 candidate Anti-CRISPR protein genes in 'Acinetobacter phage XC1'. These genes form a typical regulatory locus structure, making them promising candidates for neutralizing bacterial defense mechanisms in the future.
Testing for antimicrobial resistance (AMR) genes for safety is also an essential element. The analysis revealed that 21 AMR-like genes (amino acid identity of 22.5-47.1%) were evenly distributed. The researchers established a standard criterion to exclude high-risk phages and select only genetically harmless candidates.
Significance and Prospects
Practical Challenges and Commercialization Prospects
This study is significant in that it establishes a standard guideline that reflects multifaceted genomic information when selecting phages to inhibit carbapenem-resistant bacteria. Previously, it relied only on killing power, but by predicting efficiency and safety in advance through genomic analysis, it has opened the way to reduce the clinical failure rate. Anti-CRISPR and antimicrobial resistance profiles are expected to be established as reliable evaluation criteria for designing patient-specific phage therapies.
However, the genomic characteristics of the laboratory environment must be verified through additional clinical trials to ensure that they are normally expressed in actual infections in the human body. As Acinetobacter bacteria continue to evolve their immune systems to resist phages, a real-time monitoring system that can respond quickly to mutations must also be established. If data is accumulated through multi-center studies in the future, the realization of customized super-bacteria treatments will be further accelerated.
PURPOSE: Carbapenem-resistant Acinetobacter baumannii (CRAB) represents a critical global health threat for which existing antibiotics are increasingly inadequate. This study aimed to establish a comprehensive genomic framework for the rational prioritization of virulent Acinetobacter bacteriophages as therapeutic candidates. METHODS: We performed large-scale comparative genomic analysis of 340 virulent Acinetobacter bacteriophages, integrating phylogenetic reconstruction, pangenome analysis, CRISPR spacer-based host interaction mapping, Anti-CRISPR protein identification, and systematic antimicrobial resistance (AMR) gene screening. RESULTS: Genome sizes spanned a nearly 20-fold range, with a significant negative correlation between genome size and GC content (R² = 0.139, ρ = -0.630). Phylogenetic analysis revealed extensive divergence across multiple lineages with no dominant clade. Pangenome analysis identified 20,982 unique protein families, of which 76.2% were cloud genes, confirming a highly open genome architecture. CRISPR spacer matching yielded 1,480 high-confidence matches across 100 phage genomes, providing molecular evidence of broad historical infectivity. Anti-CRISPR profiling identified Acinetobacter phage XC1 as an exceptional therapeutic candidate harboring 55 predicted Anti-CRISPR proteins with canonical regulatory locus architecture. AMR screening identified 21 distinct AMR gene homologs (Loose RGI hits, 22.5 to 47.1% amino acid identity) distributed heterogeneously across the dataset, confirming abundant therapeutically clean candidates while flagging a subset warranting further scrutiny before therapeutic exclusion. CONCLUSION: These findings provide a multi-criteria genomic framework for rational phage candidate prioritization against multidrug-resistant Acinetobacter infections, with direct implications for evidence-based phage therapy development.
This study can be applied to scenarios where patient-specific treatments are prescribed for critically ill patients with carbapenem-resistant bacterial infections. After isolating Acinetobacter baumannii from an infected patient in a hospital, the researchers compare it with the information of 340 phages built in the genomic database. At this time, candidate groups such as 'phage XC1', which have a large number of immune-blocking proteins and high treatment efficiency, are selected, and harmful phages containing antimicrobial resistance genes are excluded during the selection process. By constructing a phage cocktail based on genomic data and proven target killing ability, the treatment start time can be shortened and the cure rate can be further improved. Furthermore, it is expected to be used as a key resource for proactively establishing a biologically safe phage library, shortening the mass production and regulatory approval processes by public health authorities.